Free Trial
→ Out of 18,347 Cryptocurrencies... This is the ONLY One (From Crypto 101 Media) (Ad)tc pixel

111 (NASDAQ:YI) Posts Earnings Results

Written by MarketBeat
Updated September 21, 2025
111 logo with Medical background

Key Points

  • 111 Inc. reported an earnings per share (EPS) of ($0.40) for the quarter, indicating a loss.
  • The stock opened at $6.03 and has a market capitalization of $52.10 million, with a PE ratio of -9.42.
  • Weiss Ratings reissued a "sell (d-)" rating on shares of 111, suggesting concerns about the company's performance.
  • Five stocks to consider instead of 111.

111 (NASDAQ:YI - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, Zacks reports. The firm had revenue of $447.51 million during the quarter.

111 Stock Down 3.7%

Shares of NASDAQ YI traded down $0.20 during midday trading on Friday, reaching $5.22. The company had a trading volume of 30,826 shares, compared to its average volume of 21,741. 111 has a one year low of $4.14 and a one year high of $11.90. The firm's fifty day moving average price is $6.68 and its 200-day moving average price is $7.57. The stock has a market cap of $45.10 million, a PE ratio of -6.21 and a beta of 0.46.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of 111 in a research report on Saturday, September 13th.

View Our Latest Research Report on YI

111 Company Profile

(Get Free Report)

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.

Further Reading

Earnings History for 111 (NASDAQ:YI)

Should You Invest $1,000 in 111 Right Now?

Before you consider 111, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.

While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover
10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.